Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

444
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

522
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
522
Angina IV: Management01:26

Angina IV: Management

493
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
493
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

655
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
655

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Low-Density Lipoprotein Cholesterol Lowering With Inclisiran Plus Usual Care in Recent Acute Coronary Syndrome: VICTORION-INCEPTION, a Randomized, Controlled, Open-Label Trial.

Journal of the American Heart Association·2026
Same author

Contemporary Trends in Percutaneous Coronary Intervention at Facilities Without On-Site Cardiac Surgery: Insights From the National Cardiovascular Data Registry.

Journal of the American College of Cardiology·2026
Same author

Baseline ECG Outperforms the Angiogram for Predicting Mortality in COVID-19-Associated STEMI: Insights From the NACMI Registry.

Journal of the Society for Cardiovascular Angiography & Interventions·2026
Same author

Clinical outcomes of aortic stenosis patients undergoing Impella-supported high-risk percutaneous coronary intervention.

Frontiers in cardiovascular medicine·2026
Same author

SCAI Door to Lactate Clearance (SCAI DLC) Cardiogenic Shock Initiative: Definition, Hypothesis, and Call to Action.

Journal of the Society for Cardiovascular Angiography & Interventions·2025
Same author

Short-Term Outcomes of Impella-Supported High-Risk Percutaneous Coronary Intervention in Surgically Ineligible Patients: Insights From PROTECT III.

Journal of the Society for Cardiovascular Angiography & Interventions·2025

相关实验视频

Updated: May 5, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.6K

预防在冠状动脉支架患者中提前停止双抗血小板治疗:来自美国心脏协会,美国心脏病学会,心血管血管学会和干预协会,美国外科医生协会和美国牙科协会的科学咨询,代表来自美国医生协会.

Cindy L Grines1, Robert O Bonow, Donald E Casey

  • 1William Beaumont Hospital.

Circulation
|January 17, 2007
PubMed
概括

完成12个月的双抗血小板治疗 (DAPT) 药物释放支架放置后至关重要. 过早停止DAPT显著增加了支架血栓形成,心脏病发作和死亡的风险.

更多相关视频

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

27.4K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

7.7K

相关实验视频

Last Updated: May 5, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.6K
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

27.4K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

7.7K

科学领域:

  • 心脏病学 心脏病学
  • 干预心脏病学 干预心脏病学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 双抗血小板治疗 (DAPT) 与阿司匹林和丁胺降低了冠状动脉支架后的心脏事件.
  • 患者和提供者过早停止DAPT治疗会增加支架血栓形成,心肌梗塞和死亡的风险.

研究的目的:

  • 为了强调坚持12个月的DAPT在药物释放支架植入后至关重要.
  • 为了教育患者和医疗保健提供者关于与过早停止DAPT相关的危险.

主要方法:

  • 这份咨询报告强调了基于关于DAPT持续时间的确立证据的临床建议.
  • 它强调患者和提供者对DAPT协议和风险的教育.

主要成果:

  • 坚持12个月的DAPT是预防心脏不良事件的关键.
  • 过早停止治疗大大增加了支架血栓形成和死亡的风险.

结论:

  • 药物释放支架的患者需要12个月的DAPT.
  • 建议将选择性手术推迟1年;如果手术不可避免,高风险患者可以考虑在术后继续服用阿司匹林.